ER/PR Positive, HER2 Negative Breast Cancer Survival Rate

ER-positive, PR-positive, HER2-negative breast cancer is the most common subtype, accounting for roughly two-thirds of all breast cancer diagnoses, and it carries the most favorable overall prognosis. Five-year survival rates for early-stage disease exceed 90% with appropriate treatment, and long-term outcomes have continued to improve as new therapies have entered routine care. But the numbers depend heavily on stage at diagnosis, node involvement, and a set of biological details that make the survival picture more nuanced than a single statistic can capture.

Stage and Node Status Are the Biggest Drivers

For hormone receptor-positive (HR+), HER2-negative breast cancer, the single most important factor in predicting long-term outcome is how far the cancer has spread at diagnosis. A woman with a small, node-negative tumor (stage I) has an excellent prognosis. As tumor size grows and lymph nodes become involved, the numbers shift meaningfully. A large meta-analysis of women who completed five years of endocrine therapy found that the risk of distant recurrence over the following 15 years ranged from about 13% for small node-negative tumors (T1N0) up to 41% for larger tumors with extensive node involvement (T2 with four to nine positive nodes).¹ A separate population-based study found a similar gradient, with late recurrence (10 to 25 years after diagnosis) in ER-positive tumors ranging from about 14% for T1N0 disease to 34% for T2N4-9.²

These numbers tell an important story: even with a favorable subtype, node-positive disease carries real long-term risk. The good news is that a woman with a small, node-negative HR+/HER2-negative tumor has roughly an 87% chance of remaining free of distant recurrence two decades after diagnosis. For women with heavier node burden, the risk is higher, but modern adjuvant treatments continue to improve those odds.

Why PR Status Matters

The shorthand “ER/PR positive” implies that both receptors are present, but not all tumors in this category are the same. Tumors that express both estrogen receptor (ER) and progesterone receptor (PR) consistently do better than those that are ER-positive but PR-negative. A large analysis of U.S. registry data found that patients with ER+/PR-negative tumors had roughly a 36% higher risk of breast cancer death compared with ER+/PR-positive patients.³ That gap held across all stages.⁴

The difference is even more pronounced in aggressive subtypes. In HER2-negative inflammatory breast cancer, which is a rare and particularly aggressive form, ER+/PR-negative tumors had a five-year breast-cancer-specific survival of only about 34%, compared with roughly 51% for ER+/PR-positive tumors.⁵ Inflammatory breast cancer is not typical of the broader category, but the finding underscores that PR expression is not just a box to check; it carries real prognostic weight. If your pathology report shows ER-positive but PR-negative disease, your oncologist may consider that when weighing treatment intensity.

The Late Recurrence Problem

One of the defining features of HR+/HER2-negative breast cancer, and something that surprises many patients, is that recurrence risk does not disappear after the commonly discussed five-year mark. Unlike HER2-positive or triple-negative subtypes, which tend to recur early or not at all, HR-positive tumors can recur at a steady rate for 20 years or more. The landmark analysis in the New England Journal of Medicine found that recurrences occurred at a fairly constant rate from year 5 through year 20 after diagnosis, even in women who had completed five years of endocrine therapy without any sign of disease.¹

This slow, persistent risk is why discussions about extended endocrine therapy and long-term follow-up are so central to this subtype. It also means that “five-year survival rate” captures only part of the picture. A woman who is cancer-free at five years still has a clinically meaningful risk of recurrence over the next decade. That risk is modest for small, node-negative tumors but can approach one in three for larger, node-positive disease over a 20-year horizon.

Age and Demographic Factors

Younger women diagnosed with HR+/HER2-negative breast cancer face a somewhat different prognosis than older women, particularly regarding late recurrence. A study of women under 45 found that the youngest group (ages 21 to 35) had the highest rate of late distant recurrence, with about a 10.7% chance of distant spread in the ten years after completing initial treatment. That rate dropped to about 5.8% for women aged 36 to 40, and to roughly 2.8% for women diagnosed between 41 and 45.⁶ A separate analysis using the U.S. SEER database confirmed that being under 40 at diagnosis was associated with a 70% higher risk of breast cancer death specifically in women with hormone receptor-positive, lower-grade tumors.⁷

Racial disparities also shape outcomes. Black women with ER-positive, HER2-negative disease face worse survival compared to White women, driven in part by lower rates of ER expression, higher tumor grades, and disparities in access to care. One study found that Black race was associated with roughly a 72% higher overall mortality hazard even after adjusting for clinical and pathologic characteristics.⁸ Troublingly, the introduction of newer drugs like CDK4/6 inhibitors has improved survival for White patients with metastatic HR+/HER2-negative disease, but that improvement has not been seen in Black or Hispanic patients so far. Two-year overall survival for White women in the metastatic setting improved from 63% to 67% after CDK4/6 inhibitors became available, while for Black women it stayed flat at 54%.⁹

Genomic Testing and Chemotherapy Decisions

For many women with early-stage HR+/HER2-negative breast cancer, one of the most consequential decisions is whether to add chemotherapy to endocrine therapy. Genomic assays like Oncotype DX have transformed how that decision is made. The test analyzes the expression of 21 genes in the tumor to generate a recurrence score that estimates both the risk of distant recurrence and the likely benefit of chemotherapy.¹⁰

The landmark TAILORx trial showed that women with node-negative, HR+/HER2-negative early-stage breast cancer whose recurrence scores fell in the mid-range (11 to 25) did just as well on endocrine therapy alone as those who also received chemotherapy. Adding chemo provided no improvement in invasive disease-free survival for this group.¹¹ That finding spared tens of thousands of women from unnecessary chemotherapy, with its attendant side effects and risks. The test is now standard practice for guiding treatment in HR+/HER2-negative, node-negative or limited node-positive disease.

Endocrine Therapy as the Backbone of Treatment

Hormone-blocking therapy is the cornerstone of treatment for ER+/HER2-negative breast cancer, and it has a larger impact on survival than any other single intervention in this subtype. For postmenopausal women, aromatase inhibitors have become the preferred choice over tamoxifen, reducing recurrence rates by about 30% compared with tamoxifen during the period of treatment, and cutting ten-year breast cancer mortality by roughly 15% in head-to-head comparisons.¹² Compared with no endocrine therapy at all, five years of an aromatase inhibitor reduces breast cancer mortality by about 40%.

The question of how long to continue endocrine therapy is actively debated. Extending aromatase inhibitor treatment from five to ten years further reduces recurrence. In one large trial, five-year disease-free survival was 95% in women who continued the drug compared with 91% in those who switched to placebo after the standard five years.¹³ However, that trial did not show an improvement in overall survival. A 2025 meta-analysis of 12 randomized trials confirmed this pattern: five additional years of aromatase inhibitor therapy after initial treatment reduced recurrence (about 11.6% vs. 15.2% from year 5 to year 15 after diagnosis) and distant recurrence, but did not significantly reduce breast cancer mortality.¹⁴ The benefit was clearest in women with node-positive disease, while for those at lower risk the gains from extended therapy need to be weighed against side effects like joint pain, bone thinning, and fatigue.

Simply being prescribed endocrine therapy is not enough; sticking with it matters enormously. A systematic review found that women who did not take their endocrine therapy as prescribed had roughly double the risk of relapse and death compared with those who adhered to their treatment plans, with hazard ratios for reduced event-free survival reaching around 2.0 or higher across multiple studies.¹⁵ The side effects of endocrine therapy are real and can significantly affect quality of life, but the survival data make a strong case for working with your oncologist to manage them rather than stopping treatment early.

CDK4/6 Inhibitors Changed the Landscape

The introduction of CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) has been the single biggest treatment advance for HR+/HER2-negative breast cancer in the past decade. In the metastatic setting, adding a CDK4/6 inhibitor to endocrine therapy reduced the risk of death by about 24% across multiple trials, regardless of whether the cancer was endocrine-sensitive or resistant, whether metastases were visceral or not, and regardless of patient age or menopausal status.¹⁶ Real-world data confirm these benefits: women receiving a CDK4/6 inhibitor as first-line treatment for metastatic disease had a median overall survival of roughly 51 months.¹⁷

These drugs have also moved into the early-stage setting. A recent meta-analysis of high-risk, early HR+/HER2-negative breast cancer showed that adding a CDK4/6 inhibitor to endocrine therapy improved invasive disease-free survival at both three and four years, with the four-year hazard ratio reaching 0.78. The benefit grew over time and was seen in both node-positive and node-negative patients.¹⁸ For patients with higher-risk early-stage disease, these drugs now represent a standard part of adjuvant treatment planning.

What Happens When Endocrine Therapy Stops Working

When HR+/HER2-negative breast cancer progresses despite endocrine therapy, a common biological culprit is a mutation in the ESR1 gene, which encodes the estrogen receptor itself. These mutations can make the cancer’s growth independent of estrogen and resistant to standard hormonal drugs. Elacestrant, an oral estrogen receptor degrader, was FDA-approved specifically for patients with ESR1-mutated, ER-positive, HER2-negative metastatic breast cancer that has progressed on prior treatment. In the EMERALD trial, patients with ESR1 mutations who had been on endocrine therapy plus a CDK4/6 inhibitor for at least a year saw median progression-free survival of 8.6 months with elacestrant, compared with just 1.9 months on standard care.¹⁹

Another option that has reshaped later-line treatment is trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate originally developed for HER2-positive cancers. Many HR+/HER2-negative tumors actually express low levels of HER2, classified as “HER2-low.” In the DESTINY-Breast04 trial, HR-positive patients with HER2-low metastatic disease who received T-DXd had a median overall survival of about 24 months, compared with roughly 17.5 months on standard chemotherapy.²⁰ Extended follow-up confirmed these results, establishing T-DXd as a standard of care after prior chemotherapy for HER2-low metastatic breast cancer.²¹ The emergence of HER2-low as a treatment-relevant category means that pathology reports now look at HER2 status with finer resolution than the old positive-or-negative binary.

Lobular Versus Ductal Histology

Most HR+/HER2-negative breast cancers are invasive ductal carcinomas, but about 10-15% are invasive lobular carcinomas (ILC). These two histological types behave differently over time. In the early years after diagnosis, their recurrence rates are similar. But starting around ten years out, lobular cancers begin to recur at a higher rate. One large population-based study found that the excess mortality rate for ILC versus IDC was significantly higher in the 10-to-15-year window after diagnosis for ER-positive disease.²² A pooled analysis of clinical trial data showed that 20-year disease-free survival was about 72% for ER-positive ILC compared with 83% for ER-positive IDC.²³

This late divergence is clinically relevant. Women with lobular breast cancer may benefit from longer surveillance and potentially extended endocrine therapy, though the decision involves the same risk-benefit calculus as for any patient. Lobular cancers also tend to metastasize to atypical sites, including the gastrointestinal tract and peritoneum, which can complicate detection of recurrence.

Lifestyle, Weight, and Bone Health

Modifiable factors also influence outcomes. Obesity at diagnosis is associated with worse survival in HR-positive breast cancer. A meta-analysis found that obesity was linked to roughly a 36% increase in breast-cancer-specific mortality among women with hormone receptor-positive disease, and that relationship held for both premenopausal and postmenopausal women.²⁴ Weight gain after diagnosis also appears to worsen prognosis: women who gained five or more kilograms after diagnosis had higher mortality than those who maintained their weight.²⁵

Bone health deserves special attention for postmenopausal women with this subtype. Aromatase inhibitors accelerate bone loss, and adjuvant bisphosphonates (drugs typically used for osteoporosis) have been shown to do more than just protect bones. A large meta-analysis of individual patient data from randomized trials found that bisphosphonates reduced bone recurrence, distant recurrence, and breast cancer mortality in postmenopausal women, with ten-year breast cancer death rates dropping from 18.0% to 14.7% in those who received the drugs.²⁶ This benefit was specific to postmenopausal women and did not depend on tumor size or node status. Bisphosphonates are now routinely considered as an add-on to adjuvant treatment for postmenopausal patients with early-stage breast cancer.

Pregnancy After Diagnosis

For younger women with HR+/HER2-negative breast cancer, the question of future fertility looms large. Endocrine therapy is typically prescribed for at least five years, and many women wonder whether pausing it to become pregnant is safe. The POSITIVE trial, which enrolled women with ER-positive early breast cancer who wished to conceive, directly addressed this question. Updated results show that temporarily interrupting endocrine therapy for pregnancy did not increase the risk of breast cancer events. The five-year cumulative incidence of recurrence was 12.3% among women who paused treatment, compared with 13.2% in a matched control group who did not.²⁷ Longer-term follow-up has continued to support the safety of this approach.²⁸ This is reassuring data for women who want to have children and who have an otherwise favorable early-stage prognosis.

Male Breast Cancer

HR+/HER2-negative breast cancer is rare in men, but when it does occur, it accounts for a disproportionately large share of male cases, roughly 78% compared with about 67% in women.²⁹ Despite this favorable biology on paper, men with HR+/HER2-negative breast cancer actually have worse overall survival than stage-matched women with the same subtype. The reasons are not fully understood but likely involve later diagnosis (men are not screened for breast cancer), less research on optimal male-specific treatment strategies, and possible biological differences in how male tumors respond to endocrine therapy. Most treatment recommendations for male breast cancer are extrapolated from data in women, which leaves a meaningful evidence gap.

How Survival Trends Have Shifted Over Time

The prognosis for HR+/HER2-negative breast cancer has improved substantially over the past three decades. From 1992 through the late 1990s, five-year survival rates improved steadily across ER/PR subtypes, driven by wider adoption of adjuvant endocrine therapy and earlier detection through screening. For ER+/PR+ disease, improvement continued at a more modest pace into the 2000s.³⁰ The hazard of dying from breast cancer has declined not only in the first five years after diagnosis but also in the later years beyond five.³¹ The arrival of CDK4/6 inhibitors in the mid-2010s, the growing role of genomic testing to spare patients from unnecessary chemotherapy, and the expansion of targeted options for advanced disease all suggest that these trends will continue. For women diagnosed today with early-stage ER+/PR+/HER2-negative breast cancer, the long-term outlook is considerably better than what the data from even a decade ago would have predicted.